| 1. Executive Summary |
| 2. Global Anti-Infective Market Introduction |
| 2.1. Global Anti-Infective Market - Taxonomy |
| 2.2. Global Anti-Infective Market -Definitions |
| 2.2.1. By Product Type |
| 2.2.2. By Indication |
| 2.2.3. By Distribution Channel |
| 2.2.4. By Region |
| 3. Global Anti-Infective Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Anti-Infective Market Dynamic Factors - Impact Analysis |
| 3.6. Global Anti-Infective Market - Competition Landscape |
| 4. Global Anti-Infective Market Analysis, 2018-2022 and Forecast, 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Anti-Infective Market, By Product Type, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1. Antibacterials |
| 5.1.1. Cephalosporins |
| 5.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.1.3. Market Opportunity Analysis |
| 5.1.2. Penicillin |
| 5.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.2.3. Market Opportunity Analysis |
| 5.1.3. Fluoroquinolones |
| 5.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3.3. Market Opportunity Analysis |
| 5.1.4. Macrolides |
| 5.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.4.3. Market Opportunity Analysis |
| 5.1.5. Carbapenems |
| 5.1.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.5.3. Market Opportunity Analysis |
| 5.1.6. Others |
| 5.1.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.6.3. Market Opportunity Analysis |
| 5.2. Antifungals |
| 5.2.1. Azoles |
| 5.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.1.3. Market Opportunity Analysis |
| 5.2.2. Echinocandins |
| 5.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.2.3. Market Opportunity Analysis |
| 5.2.3. Polyenes |
| 5.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3.3. Market Opportunity Analysis |
| 5.2.4. Others |
| 5.2.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.4.3. Market Opportunity Analysis |
| 5.3. Antivirals |
| 5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Anti-Infective Market Forecast, By Indication, 2018-2022 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 6.1. Pneumonia |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Methicillin-resistant Staphylococcus Aureus (MRSA) |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Sepsis |
| 6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Tuberculosis |
| 6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Dermatophytosis |
| 6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Aspergillosis |
| 6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Candidiasis |
| 6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 6.8. Hepatitis Virus Infection |
| 6.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.8.3. Market Opportunity Analysis |
| 6.9. HIV Infection |
| 6.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.9.3. Market Opportunity Analysis |
| 6.10. Respiratory Virus Infection |
| 6.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.10.3. Market Opportunity Analysis |
| 6.11. Others |
| 6.11.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.11.3. Market Opportunity Analysis |
| 7. Global Anti-Infective Market, By Distribution Channel, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.1. Hospital Pharmacy |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacy |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Specialty Pharmacy |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. E-commerce |
| 7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Others |
| 7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. Global Anti-Infective Market Forecast, By Region, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Anti-Infective Market - Opportunity Analysis Index, By Product Type, Indication, Distribution Channel, and Region, 2023-2029 |
| 9. North America Anti-Infective MarketAnalysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 9.1. By Product Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Antibacterials |
| 9.1.1.1. Cephalosporins |
| 9.1.1.2. Penicillin |
| 9.1.1.3. Fluoroquinolones |
| 9.1.1.4. Macrolides |
| 9.1.1.5. Carbapenems |
| 9.1.1.6. Others |
| 9.1.2. Antifungals |
| 9.1.2.1. Azoles |
| 9.1.2.2. Echinocandins |
| 9.1.2.3. Polyenes |
| 9.1.2.4. Others |
| 9.1.3. Antivirals |
| 9.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Pneumonia |
| 9.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA) |
| 9.2.3. Sepsis |
| 9.2.4. Tuberculosis |
| 9.2.5. Dermatophytosis |
| 9.2.6. Aspergillosis |
| 9.2.7. Candidiasis |
| 9.2.8. Hepatitis Virus Infection |
| 9.2.9. HIV Infection |
| 9.2.10. Respiratory Virus Infection |
| 9.2.11. Others |
| 9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Hospital Pharmacy |
| 9.3.2. Retail Pharmacy |
| 9.3.3. Specialty Pharmacy |
| 9.3.4. E-commerce |
| 9.3.5. Others |
| 9.4. Country Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. USA |
| 9.4.2. Canada |
| 9.5. North America Anti-Infective Market - Opportunity Analysis Index, By Product Type, Indication, Distribution Channel, and Country, 2023-2029 |
| 9.6. North America Anti-Infective Market Dynamics - Trends |
| 10. Europe Anti-Infective Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 10.1. By Product Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Antibacterials |
| 10.1.1.1. Cephalosporins |
| 10.1.1.2. Penicillin |
| 10.1.1.3. Fluoroquinolones |
| 10.1.1.4. Macrolides |
| 10.1.1.5. Carbapenems |
| 10.1.1.6. Others |
| 10.1.2. Antifungals |
| 10.1.2.1. Azoles |
| 10.1.2.2. Echinocandins |
| 10.1.2.3. Polyenes |
| 10.1.2.4. Others |
| 10.1.3. Antivirals |
| 10.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Pneumonia |
| 10.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA) |
| 10.2.3. Sepsis |
| 10.2.4. Tuberculosis |
| 10.2.5. Dermatophytosis |
| 10.2.6. Aspergillosis |
| 10.2.7. Candidiasis |
| 10.2.8. Hepatitis Virus Infection |
| 10.2.9. HIV Infection |
| 10.2.10. Respiratory Virus Infection |
| 10.2.11. Others |
| 10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Hospital Pharmacy |
| 10.3.2. Retail Pharmacy |
| 10.3.3. Specialty Pharmacy |
| 10.3.4. E-commerce |
| 10.3.5. Others |
| 10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Poland |
| 10.4.8. Rest of Europe |
| 10.5. Europe Anti-Infective Market - Opportunity Analysis Index, By Product Type, Indication, Distribution Channel, and Country, 2023-2029 |
| 10.6. Europe Anti-Infective Market Dynamics - Trends |
| 11. Asia-Pacific Anti-Infective Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 11.1. By Product Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Antibacterials |
| 11.1.1.1. Cephalosporins |
| 11.1.1.2. Penicillin |
| 11.1.1.3. Fluoroquinolones |
| 11.1.1.4. Macrolides |
| 11.1.1.5. Carbapenems |
| 11.1.1.6. Others |
| 11.1.2. Antifungals |
| 11.1.2.1. Azoles |
| 11.1.2.2. Echinocandins |
| 11.1.2.3. Polyenes |
| 11.1.2.4. Others |
| 11.1.3. Antivirals |
| 11.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Pneumonia |
| 11.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA) |
| 11.2.3. Sepsis |
| 11.2.4. Tuberculosis |
| 11.2.5. Dermatophytosis |
| 11.2.6. Aspergillosis |
| 11.2.7. Candidiasis |
| 11.2.8. Hepatitis Virus Infection |
| 11.2.9. HIV Infection |
| 11.2.10. Respiratory Virus Infection |
| 11.2.11. Others |
| 11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Hospital Pharmacy |
| 11.3.2. Retail Pharmacy |
| 11.3.3. Specialty Pharmacy |
| 11.3.4. E-commerce |
| 11.3.5. Others |
| 11.4. Country Analysis2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Japan |
| 11.4.2. China |
| 11.4.3. India |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Anti-Infective Market - Opportunity Analysis Index, By Product Type, Indication, Distribution Channel, and Country, 2023-2029 |
| 11.6. Asia-Pacific Anti-Infective Market Dynamics - Trends |
| 12. Latin America Anti-Infective Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 12.1. By Product Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Antibacterials |
| 12.1.1.1. Cephalosporins |
| 12.1.1.2. Penicillin |
| 12.1.1.3. Fluoroquinolones |
| 12.1.1.4. Macrolides |
| 12.1.1.5. Carbapenems |
| 12.1.1.6. Others |
| 12.1.2. Antifungals |
| 12.1.2.1. Azoles |
| 12.1.2.2. Echinocandins |
| 12.1.2.3. Polyenes |
| 12.1.2.4. Others |
| 12.1.3. Antivirals |
| 12.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Pneumonia |
| 12.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA) |
| 12.2.3. Sepsis |
| 12.2.4. Tuberculosis |
| 12.2.5. Dermatophytosis |
| 12.2.6. Aspergillosis |
| 12.2.7. Candidiasis |
| 12.2.8. Hepatitis Virus Infection |
| 12.2.9. HIV Infection |
| 12.2.10. Respiratory Virus Infection |
| 12.2.11. Others |
| 12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Hospital Pharmacy |
| 12.3.2. Retail Pharmacy |
| 12.3.3. Specialty Pharmacy |
| 12.3.4. E-commerce |
| 12.3.5. Others |
| 12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Argentina |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America Anti-Infective Market - Opportunity Analysis Index, By Product Type, Indication, Distribution Channel, and Country, 2023-2029 |
| 12.6. Latin America Anti-Infective Market Dynamics - Trends |
| 13. Middle East and Africa Anti-Infective Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 13.1. By Product Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Antibacterials |
| 13.1.1.1. Cephalosporins |
| 13.1.1.2. Penicillin |
| 13.1.1.3. Fluoroquinolones |
| 13.1.1.4. Macrolides |
| 13.1.1.5. Carbapenems |
| 13.1.1.6. Others |
| 13.1.2. Antifungals |
| 13.1.2.1. Azoles |
| 13.1.2.2. Echinocandins |
| 13.1.2.3. Polyenes |
| 13.1.2.4. Others |
| 13.1.3. Antivirals |
| 13.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Pneumonia |
| 13.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA) |
| 13.2.3. Sepsis |
| 13.2.4. Tuberculosis |
| 13.2.5. Dermatophytosis |
| 13.2.6. Aspergillosis |
| 13.2.7. Candidiasis |
| 13.2.8. Hepatitis Virus Infection |
| 13.2.9. HIV Infection |
| 13.2.10. Respiratory Virus Infection |
| 13.2.11. Others |
| 13.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Hospital Pharmacy |
| 13.3.2. Retail Pharmacy |
| 13.3.3. Specialty Pharmacy |
| 13.3.4. E-commerce |
| 13.3.5. Others |
| 13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. Israel |
| 13.4.3. South Africa |
| 13.4.4. Rest of MEA |
| 13.5. MEA Anti-Infective Market - Opportunity Analysis Index, By Product Type, Indication, Distribution Channel, and Country, 2023-2029 |
| 13.6. MEA Anti-Infective Market Dynamics - Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Indication& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Gilead Sciences |
| 14.2.2. GlaxoSmithKline |
| 14.2.3. Merck & Co |
| 14.2.4. Johnson & Johnson |
| 14.2.5. Pfizer Inc. |
| 14.2.6. AbbVie |
| 14.2.7. Bayer AG |
| 14.2.8. Mylan N.V. |
| 14.2.9. Shionogi |
| 14.2.10. F. Hoffmann-La Roche Ltd |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
hghLatin America Got Significant Share
Anti Infective Market
Latin America
Europe
Asia Pacific
Middle East
North America
Frequently Asked Questions
2023 is the base year and 2030 is the forecast year.
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
The anti-infective market key players are: Gilead Sciences, GlaxoSmithKline, Merck & Co, Johnson & Johnson, Pfizer Inc., AbbVie, Bayer AG, Mylan N.V., Shionogi, Hoffmann-La Roche Ltd
Key Features of the Report
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- Gilead Sciences
- GlaxoSmithKline
- Merck & Co
- Johnson & Johnson
- Pfizer Inc.
- AbbVie
- Bayer AG
- Mylan N.V.
- Shionogi
- Hoffmann-La Roche Ltd